Lactoferrin Market

How big is Lactoferrin Market in 2026?

The lactoferrin market is valued at USD 268.2 million in 2026 and is projected to reach USD 457.9 million by 2036, growing at a 5.0% CAGR.

The lactoferrin market is valued at USD 268.2 Million in 2026 and is forecast to reach USD 457.9 Million by 2036 at a 5.0% CAGR. Formula and adult-nutrition makers buy lactoferrin for a specific product, not simply to add more protein. Identity, purity; use conditions and reliable supply have to be documented. In January 2025, FrieslandCampina said it had concluded that Vivinal Lactoferrin was GRAS for specified US formula uses after FDA issued a decline-to-file letter. That is a company safety conclusion for a named ingredient not a blanket FDA approval of lactoferrin products. The 2025 base is estimated at USD 255.4 Million.

Birth counts point to different sales mixes across countries. South Korea recorded 254,341 live births in 2025, while Germany's 2025 birth count remained low. Japan has a substantial older population as well as a smaller infant cohort. Those facts affect how much attention suppliers put on early-life formulas; adult nutrition and clinical products. In each channel; a useful claim still needs product-specific evidence and a protein that behaves predictably in the chosen format.

Key Takeaways of Lactoferrin Market

• Demand mechanism: Demand is concentrated in applications where formulators pay for documented purity, regulatory suitability and dependable specialty-protein supply.
• Form leader: Powder leads the Form category in 2026 because commercial isolation processes commonly finish with drying that supports storage and formulation handling.
• Application leader: Infant Formulas lead the Application category in 2026 because lactoferrin has established regulatory use pathways in premium early-life formulations.
• Diversification: Broader adult-nutrition and specialty-food uses create diversification potential, but they require application-specific evidence and compliant claims rather than a simple transfer of infant-formula positioning.
• Purchasing friction: The main purchasing friction is qualification of a high-purity ingredient from a process that is technically specialized and difficult to switch without validation.
• Profiled current companies: Fonterra Co-operative Group Ltd., FrieslandCampina, Glanbia plc; Synlait Milk Ltd.; Ingredia SA; Hilmar Cheese Company; MP Biomedicals; Tatura Milk Industries Ltd. and Farbest Brands.

Analyst Perspective

An infant-formula buyer needs a lactoferrin specification it can defend in its own safety and quality file. A supplier that cannot reproduce purity and delivery from lot to lot will struggle to keep that account.

- Nandini Roy Choudhury, Principal Consultant, Future Market Insights

How is the Lactoferrin Market segmented?

The lactoferrin market is segmented by Form and Application.

The lactoferrin market uses two segment axes that separate physical handling requirements from downstream formulation environments.
Form covers powder and liquid.
Application covers infant formulas, sports nutrition, food nutrition, veterinary nutrition, clinical nutrition, personal care, and others.

What keeps Infant Formulas central to the Application category?

Infant formula is the largest application because the purchase case is built around a defined nutritional formulation rather than an undifferentiated protein addition. FDA GRAS records and European Union authorizations explicitly address bovine lactoferrin use in infant-formula categories. That regulatory history supports a qualification pathway for suppliers while also raising the evidence threshold. Formula manufacturers therefore place unusual weight on safety documentation, manufacturing consistency and traceability. A 2025 Swedish randomized follow-up found that reducing iron fortification in infant formula from 8 to 2 mg/L did not increase the risk of iron deficiency or impair neurodevelopment at 12 months. Broad benefit claims for lactoferrin still need application-specific evidence rather than reliance on regulatory permission alone.

• Infant Formulas hold a 38.0% share of the Application category in 2026 because infant-formula buyers can assess bovine lactoferrin against defined safety pathways and exacting ingredient specifications.
• In January 2025, FrieslandCampina Ingredients reported GRAS status for Vivinal Lactoferrin in specified U.S. infant and toddler formulas. The action widened its addressable early-life customer base in the United States.

Why does Powder dominate the Form category?

Powder is the working form for many lactoferrin buyers. It can be weighed into a dry blend, transported without a chilled liquid chain and stored under controlled conditions. Supplier processing generally uses separation and drying to deliver a concentrated grade. The buyer then checks purity, solubility and stability in the intended formula. Current product ranges from FrieslandCampina; Fonterra and Ingredia show that powder specification; rather than the mere availability of the protein; is the practical purchasing question.

• Powder holds a 90.0% share of the Form category in 2026 because spray-dried output can enter dry nutrition blends without moving a liquid carrier through the supply chain.
• In January 2025, FrieslandCampina announced its GRAS conclusion for Vivinal Lactoferrin in specified US formula uses following an FDA decline-to-file letter.

What are the drivers, restraints and opportunities in the Lactoferrin Market?

In the lactoferrin market, the key driver is the continued search by early-life formulators for differentiated milk-derived bioactive ingredients that can meet established safety and manufacturing requirements, making powder the dominant working form since spray-dried output can enter dry nutrition blends without moving a liquid carrier through the supply chain, the key restraint is that high-purity fractionation and application qualification make capacity expansion and supplier replacement slower than ordinary dairy-protein sourcing, since a buyer must check purity, functional properties and batch consistency before approving a new source, and the key opportunity is the diversification of demand into sports, food, clinical and personal-care uses, which can expand the addressable market when suppliers build the application-specific evidence and claims each format requires rather than simply transferring infant-formula positioning across categories.

• Driver: Early-life formulators continue to seek differentiated milk-derived bioactive ingredients that can meet established safety and manufacturing requirements.
• Restraint: High-purity fractionation and application qualification make capacity expansion and supplier replacement slower than ordinary dairy-protein sourcing.
• Opportunity: Sports, food, clinical and personal-care uses can diversify demand when suppliers build evidence and claims that fit each application.

Premium nutrition buyers need an ingredient they can trace and defend in a particular formula. FrieslandCampina's January 2025 announcement gives a recent example: the company concluded that Vivinal Lactoferrin was GRAS for specified formula uses after an FDA decline-to-file letter. That conclusion does not prove a finished product's claims. Stable purity, batch records and technical help still matter when a buyer moves from a test batch to regular orders.

Lactoferrin is separated from dairy streams through selective processing, so switching supplier is more involved than replacing a commodity protein. A buyer will check purity, functional properties and batch consistency before approving a new source. Synlait's FY2025 update described active lactoferrin sales but a company-level sales movement does not tell us whether a particular formula maker can use another grade. Qualification and continuity remain the practical brakes on a quick change.

A formula maker and a sports-nutrition brand may buy the same named protein for very different reasons. Fonterra lists lactoferrin through Nutiani and NZMP; Glanbia offers Bioferrin in powders, bars, tablets and capsules; Hilmar positions Beneferrin for sports and healthy-living products. A supplier must explain purity; dose and suitable claims for each customer. That work can open orders beyond infant formula without implying that one health claim travels across every format.

Which country CAGRs are profiled in the Lactoferrin Market?

Country	CAGR
South Korea	11.0%
Brazil	10.0%
USA	9.0%
Indonesia	8.0%
France	7.0%
Japan	6.0%
UK	5.0%
Germany	4.0%

How do country-level CAGRs compare in the lactoferrin market?

The profiled growth rates separate into a high-growth group led by South Korea, Brazil and the USA and a middle band spanning Indonesia through Japan. The UK and Germany form the slower-growth end. The highest-to-lowest spread is 7.0 percentage points. These rates describe forecast momentum rather than absolute market size, so supplier prioritization should also consider application mix and regulatory access.

• South Korea: A recent rebound in births improves the near-term early-life signal, although the rate does not imply the largest revenue pool.
• Brazil: Regulatory control over authorized supplement constituents and claims makes compliance preparation a decisive route-to-market condition.
• USA: A clear FDA GRAS history gives infant-formula suppliers a defined safety pathway, but customer qualification remains exacting.
• Indonesia: Fertility near replacement level and a rising older population support a more balanced early-life and adult-nutrition demand case.
• France: Falling births weaken a volume-led infant thesis and increase the importance of adult and specialty applications.
• Japan: A very old population and a shrinking birth cohort shift the growth case toward premiumization and adult nutrition rather than infant volume.
• UK: The 2025 birth count gives infant-formula suppliers a defined customer base; specialty applications depend on product qualification.
• Germany: The lowest profiled CAGR aligns with a mature market and a sharply reduced birth cohort.

Birth patterns, adult-nutrition demand and local claim rules vary across South Korea, Brazil; the USA; Indonesia; France; Japan; the UK and Germany.

Country-wise Analysis

• South Korea has the highest profiled rate, at 11.0% CAGR from 2026 to 2036. The national statistics portal records 254,341 live births in 2025. That creates a defined early-life customer base; though births alone do not predict lactoferrin sales. Formula makers need a qualified ingredient and a reason to add it at a viable dose and price. Adult specialty nutrition provides another route if a supplier can meet its different claim and format requirements.
• Brazil's profile indicates a 10.0% CAGR from 2026 to 2036. The most important commercial condition is regulatory control over how specialty ingredients enter supplements and other foods. Anvisa states that only authorized constituents may be used in supplements and that permitted benefit claims are controlled by the agency. That framework raises the value of a complete technical and regulatory package for distributors and formulators. Growth can therefore be fast without being frictionless. Suppliers need local regulatory interpretation and disciplined claim support. Commercial partners with strong importer or formulation capabilities can shorten the path from an ingredient specification to a compliant consumer product.
• The USA is profiled at 9.0% CAGR from 2026 to 2036. In January 2025, FrieslandCampina announced its GRAS conclusion for specified Vivinal Lactoferrin formula uses after an FDA decline-to-file letter. CDC recorded 3.6064 million births in 2025. That is a large potential early-life base, but suppliers still have to win accounts through documented composition; suitable use and reliable delivery. Adult nutrition gives manufacturers another reason to test the protein where its cost can be justified.
• Indonesia: The 2026 to 2036 CAGR for Indonesia is 8.0%. BPS-Statistics Indonesia reported a total fertility rate of 2.13 in the 2025 intercensal survey and said 11.97% of the population was older. That combination supports two demand directions. Early-life nutrition remains relevant while adult health and healthy-aging formulations can become more important over the forecast period. The challenge is commercial execution across a large archipelago with varied channels and importer relationships. Dry powder can move through national ingredient distribution more readily than a liquid specialty protein; formulators can then assess it for either early-life or adult products.
• France carries a 7.0% CAGR in the 2026 to 2036 profile. INSEE recorded 643,905 births in 2025. For a supplier, that is a sizeable but finite infant-formula market. Growth may also come from adult nutrition and specialist food products; provided the formulation and claims are appropriate. A higher-purity grade or better handling characteristic matters commercially only when a French customer can use it in a product that people will buy repeatedly.
• Japan is profiled at 6.0% CAGR from 2026 to 2036. Health-ministry data released in 2026 put 2025 births at about 706,000. Formula demand therefore has a clear demographic limit. Adult and clinical nutrition may offer a wider set of applications, but buyers will expect precise specifications and evidence for each use. A supplier has to show how its lactoferrin performs in the actual drink; powder or other finished product before seeking long-term volume.
• The UK is profiled at 5.0% CAGR from 2026 to 2036. The Office for National Statistics recorded 585,396 live births in England and Wales in 2025 and provisionally estimated a total fertility rate of 1.39. These figures make a volume-only infant story unconvincing. Premium formulas, sports nutrition and clinical products each present a different purchasing case. Suppliers need to make that case with a clear composition and a claim that fits the intended product.
• Germany has the lowest profiled rate, at 4.0% CAGR from 2026 to 2036. Destatis recorded approximately 654,300 births in 2025, the lowest total since 1946. That number defines one early-life customer pool while adult nutrition and specialized foods present separate uses. A lactoferrin supplier still needs a qualified ingredient; suitable claims and a formulation that works for the buyer. Germany's established nutrition industry offers potential accounts but population data alone do not establish demand for this protein.

Who are the notable companies in the Lactoferrin Market?

Fonterra Co-operative Group Ltd., FrieslandCampina, Glanbia plc, Synlait Milk Ltd., Ingredia SA, Hilmar Cheese Company, MP Biomedicals, Tatura Milk Industries Ltd. and Farbest Brands are the notable companies profiled in this market.

Competition spans large dairy processors, specialist ingredient manufacturers and smaller channel or research suppliers. Fonterra Co-operative Group Ltd., FrieslandCampina; Glanbia plc; Synlait Milk Ltd.; Ingredia SA; Hilmar Cheese Company and Tatura Milk Industries Ltd. are tied to dairy fractionation or commercial nutrition ingredients. MP Biomedicals sells purified human lactoferrin for research use and therefore occupies a different buying context. Farbest Brands operates as a North American ingredient distributor with a commercial lactoferrin offer. These roles create different strengths in scale; qualification; application support and route to market.

• Integrated dairy bioactive manufacturers: Fonterra Co-operative Group Ltd.; FrieslandCampina; Glanbia plc; Synlait Milk Ltd.; Ingredia SA; Hilmar Cheese Company; Tatura Milk Industries Ltd.
• Specialty research and distribution channels: MP Biomedicals; Farbest Brands.
• Research-use supply: MP Biomedicals lists purified human lactoferrin for laboratory buyers, a distinct channel from food-ingredient sales.

Competitive Benchmarking: Lactoferrin Market

Company	Commercial Ingredient Scale	Infant-Nutrition Qualification	Application Breadth	Geographic Reach
Fonterra Co-operative Group Ltd.	High	Medium	High	New Zealand manufacturing with commercial reach through global NZMP and Nutiani networks
FrieslandCampina	High	High	High	Europe-based production with commercial ingredient operations across major global nutrition markets
Glanbia plc	Medium	Medium	High	Global nutrition ingredient network with sales locations across North America, Europe and Asia-Pacific
Synlait Milk Ltd.	High	Medium	Medium	New Zealand production with multinational nutrition customers and export orientation
Ingredia SA	Medium	Low	Medium	France-based production with subsidiaries in North America and Asia-Pacific
Hilmar Cheese Company	Medium	Medium	Medium	United States manufacturing with documented nutrition applications and customer inquiry channels
MP Biomedicals	Low	Low	Low	Worldwide research-product distribution; lactoferrin product is documented for research use only
Tatura Milk Industries Ltd.	High	Medium	High	Australian production within Bega Group with international ingredient customers
Farbest Brands	Medium	Low	High	North American distribution with commercial lactoferrin supply for multiple formulation categories

Scoring basis: Commercial Ingredient Scale is High when public evidence shows dedicated high-purity production with substantial integrated supply, Medium when a credible commercial product is documented but public scale evidence is narrower and Low only where a documented small research-use format limits commercial scale. Infant-Nutrition Qualification is High when direct regulatory evidence and an infant-formula offer are documented, Medium when early-life capability is documented without the same direct regulatory evidence and Low where the documented product is research-use only. Application Breadth is High when multiple supplied application categories are documented; Medium when coverage is narrower and Low where the public product is confined to research use. Low indicates a documented limitation.

Key Developments in the Lactoferrin Market

• In January 2025, FrieslandCampina said Vivinal Lactoferrin was GRAS for specified US infant and toddler formula uses. FDA issued a decline-to-file letter because the submitted material was substantially similar to earlier notices. The company's safety conclusion provides a current reference for the named ingredient; it is not an FDA no-questions letter or approval of a finished formula.

Key Players in the Lactoferrin Market

Integrated Dairy Bioactive Manufacturers

• Fonterra Co-operative Group Ltd.
• FrieslandCampina
• Glanbia plc
• Synlait Milk Ltd.
• Ingredia SA
• Hilmar Cheese Company
• Tatura Milk Industries Ltd.

Specialty Research and Distribution Channels

• MP Biomedicals
• Farbest Brands

Lactoferrin Market - Report Scope

Coverage field	Report scope
Market breakdown	Form: Powder, Liquid. Application: Infant Formulas, Sports Nutrition, Food Nutrition, Veterinary Nutrition, Clinical Nutrition, Personal Care, Others.
Quantitative Units	USD Million
Market Definition	Includes revenue from lactoferrin ingredient sold as Powder or Liquid into the defined application universe. Excludes revenue from finished infant formulas, supplements, foods, veterinary products, clinical formulas and personal-care products. Adjacent dairy fractions, substitute proteins and downstream finished-product revenue are excluded.
Regions Covered	North America; Latin America; Western Europe; Eastern Europe; East Asia; South Asia and Pacific; Middle East and Africa
Countries Covered	USA; Japan; Germany; Brazil; UK; France; Indonesia; South Korea
Key Companies Profiled	Fonterra Co-operative Group Ltd.; FrieslandCampina; Glanbia plc; Synlait Milk Ltd.; Ingredia SA; Hilmar Cheese Company; MP Biomedicals; Tatura Milk Industries Ltd.; Farbest Brands
Forecast Period	2026 to 2036
Approach	Named ingredient records and 2025 demographics reviewed alongside FMI market estimates.

Lactoferrin Market - Research Methodology

Method	Approach
Market Scope	The analysis focuses on qualified lactoferrin ingredients for early-life and adult nutrition, while keeping research-use material separate from food ingredients.
Public Evidence	Supplier releases, current product listings and national 2025 birth counts give product and demographic context. A GRAS outcome is attributed to the named ingredient and use, not the entire category.
Forecast Interpretation	FMI forecasts supply the market totals and country CAGRs. Birth counts are not converted into lactoferrin sales without an adoption rate, dose and product mix.
Source Checks	Product identity, purity and intended use were checked separately. Company references without a current lactoferrin offer were not treated as evidence of active supply.

Lactoferrin Market by Segments

Lactoferrin Market segmented by Form

• Powder
• Liquid

Lactoferrin Market segmented by Application

• Infant Formulas
• Sports Nutrition
• Food Nutrition
• Veterinary Nutrition
• Clinical Nutrition
• Personal Care
• Others

Lactoferrin Market by Region

• North America
  • United States
  • Canada
• Latin America
  • Brazil
  • Mexico
  • Argentina
  • Chile
• Western Europe
  • Germany
  • France
  • United Kingdom
  • Italy
  • Spain
  • Benelux
  • Nordics
• Eastern Europe
  • Poland
  • Czech Republic
  • Romania
  • Hungary
• East Asia
  • China
  • Japan
  • South Korea
• South Asia and Pacific
  • India
  • ASEAN
  • Australia and New Zealand
• Middle East and Africa
  • GCC Countries
  • South Africa
  • Türkiye
  • Israel

Research Sources and Bibliography

• U.S. Food and Drug Administration (n.d.). GRAS Notice No. 465: Cow's milk-derived lactoferrin.
• FrieslandCampina Ingredients (2025, January 16). Vivinal Lactoferrin achieves GRAS status for US infant nutrition market.
• FrieslandCampina Ingredients (n.d.). Lactoferrin.
• FrieslandCampina Ingredients (n.d.). About us.
• Nutiani (n.d.). Nutiani Lactoferrin.
• NZMP (n.d.). Lactoferrin - Speciality Ingredients.
• NZMP (n.d.). Global Ingredients Network.
• Glanbia Nutritionals (n.d.). Bioactive Ingredients.
• Glanbia Nutritionals (n.d.). Contact.
• Synlait Milk Ltd. (2025, September 29). Annual Report 2025.
• Ingredia SA (n.d.). Dairy-based bioactive ingredients.
• Ingredia SA (n.d.). Our facilities.
• Ingredia SA (n.d.). Our heritage.
• Hilmar Cheese Company (n.d.). Beneferrin Lactoferrin.
• Hilmar Cheese Company (n.d.). Markets.
• Islamic Food and Nutrition Council of America (2025, May 13). Halal Product Certificate: 1000 Lactoferrin Freeze-dried.
• MP Biomedicals (n.d.). Purified Human Lactoferrin.
• MP Biomedicals (n.d.). Our Locations.
• Bega Bionutrients (n.d.). About us.
• Farbest Brands (n.d.). Lactoferrin.
• Farbest Brands (n.d.). About Farbest.
• National Center for Health Statistics (2026, April 9). Births: Provisional Data for 2025.
• BPS-Statistics Indonesia (2026, May 5). SUPAS 2025: The Total Fertility Rate is 2.13 and the percentage of older persons has reached 11.97 percent.
• INSEE (2026, July 6). Births in 2025: A Continuing Decrease in the Number of Births.
• Office for National Statistics (2026, May 27). Births in England and Wales: 2025.
• ANVISA (n.d.). Consult the list of authorized ingredients.
• Björmsjö, M. et al. (2025, November 27). Infant formula iron fortification of 2 vs. 8 mg/L does not increase the risk of iron deficiency or impact neurodevelopment at 12 months.
• Korean Statistical Information Service, 2025 live-birth total
• Japan Ministry of Health, Labour and Welfare, 2026 release on 2025 births
• Ingredia Health, February 2025 FIC ingredient release
• Nutiani, current lactoferrin ingredient listing
• Bega Group, 2025 annual report

This Report Answers

• How large is the Lactoferrin Market in 2026 and what value is forecast for 2036?
• Which industry pressures support demand for lactoferrin ingredients?
• Why does Powder hold the leading position in the Form category?
• Why do Infant Formulas hold the leading position in the Application category?
• How do the profiled country growth rates differ from 2026 to 2036?
• Which companies supply lactoferrin across nutrition, research and distribution channels?
• What limits adoption or supplier switching for high-purity lactoferrin?
• What should buyers evaluate before purchasing a lactoferrin ingredient?